Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapy

Trial Profile

Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2017

At a glance

  • Drugs Resminostat (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Yakult Honsha
  • Most Recent Events

    • 30 Jan 2017 Primary endpoint (Progression-free survival) has not been met.
    • 30 Jan 2017 Results published in the Investigational New Drugs
    • 11 Jul 2016 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top